WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

ATC level alterations

List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.

Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.

Previous ATC codeATC level nameNew ATC codeDeadline for objection to temporary alterations Implementation in ATC/DDD index
J06BB16palivizumabJ06BD0101.09.20212022
J06BB17motavizumabJ06BD0201.09.20212022
J06BB18raxibacumabJ06BC0201.09.20212022
J06BB21bezlotoxumabJ06BC0301.09.20212022
J06BB22obiltoxaximabJ06BC0401.09.20212022
L01EX16erdafitinibL01EN0101.09.20212022
L01EX20pemigatinibL01EN0201.09.20212022
L01XCMonoclonal antibodiesdeleted01.09.20212022
L01XC01edrecolomabL01FX0101.09.20212022
L01XC02rituximabL01FA0101.09.20212022
L01XC03trastuzumabL01FD0101.09.20212022
L01XC05gemtuzumab ozogamicinL01FX0201.09.20212022
L01XC06cetuximabL01FE0101.09.20212022
L01XC07bevacizumabL01FG0101.09.20212022
L01XC08panitumumabL01FE0201.09.20212022
L01XC09catumaxomabL01FX0301.09.20212022
L01XC10ofatumumabL01FA0201.09.20212022
L01XC11ipilimumabL01FX0401.09.20212022
L01XC12brentuximab vedotinL01FX0501.09.20212022
L01XC13pertuzumabL01FD0201.09.20212022
L01XC14trastuzumab emtansineL01FD0301.09.20212022
L01XC15obinutuzumabL01FA0301.09.20212022
L01XC16dinutuximab betaL01FX0601.09.20212022
L01XC17nivolumabL01FF0101.09.20212022
L01XC18pembrolizumabL01FF0201.09.20212022
L01XC19blinatumomabL01FX0701.09.20212022
L01XC21ramucirumabL01FG0201.09.20212022
L01XC22necitumumabL01FE0301.09.20212022
L01XC23elotuzumabL01FX0801.09.20212022
L01XC24daratumumabL01FC0101.09.20212022
L01XC25mogamulizumabL01FX0901.09.20212022
L01XC26inotuzumab ozogamicinL01FB0101.09.20212022
L01XC27olaratumabL01FX1001.09.20212022
L01XC28durvalumabL01FF0301.09.20212022
L01XC29bermekimabL01FX1101.09.20212022
L01XC31avelumabL01FF0401.09.20212022
L01XC32atezolizumabL01FF0501.09.20212022
L01XC33cemiplimabL01FF0601.09.20212022
L01XC34moxetumomab pasudotoxL01FB0201.09.20212022
L01XC35tafasitamabL01FX1201.09.20212022
L01XC36enfortumab vedotinL01FX1301.09.20212022
L01XC37polatuzumab vedotinL01FX1401.09.20212022
L01XC38isatuximabL01FC0201.09.20212022
L01XC39belantamab mafodotinL01FX1501.09.20212022
L01XC40dostarlimabL01FF0701.09.20212022
L01XC41trastuzumab deruxtecanL01FD0401.09.20212022
L01XC42prolgolimabL01FF0801.09.20212022

Last updated: 2021-05-12